Wir sind mit live! Mehr erfahren
CCCC-Symbol

C4 Therapeutics
CCCC

2,77 USD
-0,01
0,36 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
2,76
-0,01
0,36 %
1 Tag
-0,36 %
5 Tage
-12,34 %
1 Monat
-19,71 %
3 Monate
-22,63 %
6 Monate
-4,48 %
Seit Jahresbeginn
43,52 %
1 Jahr
11,69 %
5 Jahre
-93,55 %
10 Jahre
-89,13 %
 

Profil: C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Mitarbeiter: 104

Gesundheitswesen Biotechnologie

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 20 %
Neutral 40 %
Negativ 40 %
Neutral
GlobeNewsWire
vor 22 Tagen
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Negativ
Zacks Investment Research
vor 24 Tagen
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Neutral
GlobeNewsWire
letzten Monat
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting.
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
Positiv
Zacks Investment Research
letzten Monat
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Negativ
Zacks Investment Research
vor 2 Monaten
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Positiv
Zacks Investment Research
vor 3 Monaten
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Positiv
Zacks Investment Research
vor 3 Monaten
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Neutral
Seeking Alpha
vor 4 Monaten
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Negativ
Zacks Investment Research
vor 4 Monaten
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Neutral
GlobeNewsWire
vor 4 Monaten
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Nachrichtenrankings ansehen
Kursdiagramme mit Lightweight Charts™ umgesetzt